Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Three years into designing for clinical trials, every design choice serves one question: will a user trust this system enough to act through it, or will they hedge their bets with supplemental tools? Four principles have come to guide my answer to that question.
Lindus recently submitted a public comment to the FDA on the AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program (Docket No. FDA-2026-N-4390). We support the pilot and believe it can be designed to answer harder questions than the request for information currently sets up.
At Lindus, we believe AI will empower our tech organization to build better products. LLMs are unlocking potential across product management, design, and engineering, in ways that would have seemed far-fetched even two years ago. But the way we work is changing fast, and we think it's worth sharing what that looks like in practice.
What James Lind would ask us on Clinical Trials Day is whether the systems we have built are worthy of the participants, sites, investigators, and teams who make clinical research possible.We do not think they are yet, but we know they can be.